BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Protalix BioTherapeutics\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Protalix BioTherapeutics\, Inc.'s
  drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05710692-10978@assetmemo.bio
DTSTAMP:20261121T005944Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:pegunigalsidase alfa: Phase 2/3 readout est. (NCT05710692)
DESCRIPTION:pegunigalsidase alfa\, phase 2/3\, Fabry Disease.\nStudy: Study
  to Evaluate the Safety\, PK\, PD\, and Efficacy of PRX-102 in Japanese Pa
 tients With Fabry Disease\nEstimated primary completion: October 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/pegunigalsidase-alfa#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0571069
 2
URL:https://assetmemo.bio/drug/pegunigalsidase-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07280156-10979@assetmemo.bio
DTSTAMP:20261121T005944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:PRX-115: Phase 2 readout est. (NCT07280156)
DESCRIPTION:PRX-115\, phase 2.\nStudy: A Study to Investigate the Clinical 
 Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing
  Regimens\, With and Without Methotrexate\, Versus Placebo in Adults Gout 
 Patients (RELEASE)\nEstimated primary completion: December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/prx-115#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07280156
URL:https://assetmemo.bio/drug/prx-115#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06328608-10978@assetmemo.bio
DTSTAMP:20261121T005944Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:pegunigalsidase alfa: Phase 2/3 readout est. (NCT06328608)
DESCRIPTION:pegunigalsidase alfa\, phase 2/3\, Fabry Disease.\nStudy: A Stu
 dy to Learn About the Safety and Effects of the Study Drug PRX-102 in Chil
 dren and Adolescents With Fabry Disease\nEstimated primary completion: Oct
 ober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pegunigals
 idase-alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06328608
URL:https://assetmemo.bio/drug/pegunigalsidase-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
